1 Protocol for ¹⁸F-PSMA PET imaging in staging and management of prostate

2

cancer - a retrospective cohort study

- 3 Matthew H V Byrne¹, Nithesh Ranasinha¹, Richard J Bryant¹, Freddie C Hamdy¹,
- 4 Tom Leslie¹, Saiful Miah¹, Fergus Gleeson¹, Ruth MacPherson¹, Mark Tuthill¹, Andy
- 5 Protheroe¹, Philip Camilleri¹, Phil Turner¹, Ami Sabharwal¹, Gerard Andrade¹,
- 6 Alastair D Lamb^{1,2}
- 7
- ¹Oxford University Hospitals NHS Foundation Trust, UK
- 9

10 Corresponding author

- 11 Name: Matthew H V Byrne
- 12 Email address: mhvbyrne@doctors.org.uk
- 13 Full Institution address: Churchill Hospital, Old Road, Headington, Oxford, UK
- 14 Institution postcode: OX3 7LE

15

- 16 **Funding declarations**: None
- 17 **Conflicts of interests**: None
- 18 Study type: Protocol
- 19 **Running title:** 18F PSMA PET prostate cancer protocol

20

21 **Key words:** PSMA PET, Fluorine-18, prostate cancer

22

23 Word count: 1328

- 25 **Ethics:** This study was approved as a service evaluation by the Audit Department at
- 26 Oxford University Hospitals Trust, UK and ethical approval was not required for this
- 27 study.

28 ABSTRACT

- 29 Background: MRI, bone scan, and CT staging is recommended in the staging of
- 30 prostate cancer. However, prostate-specific membrane antigen positron emission
- 31 tomography (PSMA PET) could be superior in detection of local and distant prostate
- 32 cancer cells. Most PSMA PET scans for prostate cancer are performed with a
- 33 Gallium-68 ligand, with the Fluorine-18 (¹⁸F) ligand being introduced more recently.
- 34 Methods: We will conduct a retrospective review of electronic patient records for all
- 35 consecutive patients who underwent preoperative ¹⁸F-PSMA PET scan for prostate
- 36 cancer from its introduction at our centre in 2019. We will compare PET scans with
- 37 other imaging modalities and evaluate its use in diagnosis and management
- 38 decisions for prostate cancer.
- 39 Conclusions: Understanding the role of ¹⁸F-PSMA PET in diagnosis and
- 40 management could influence the diagnostic pathway of primary and secondary
- 41 prostate cancer.
- 42 Trial registration: Not applicable.

43 BACKGROUND

44	European Association of Urology guidelines recommend the use of magnetic
45	resonance imaging (MRI) to assess local staging of prostate cancer alongside
46	computer tomography (CT) and a bone scan to assess distant metastasis in patients
47	with higher risk disease ¹ . However, MRI and CT have low sensitivity ^{2,3} , and MRI
48	has low specificity for detecting lymph node metastasis $^{4-6}$. This is problematic as
49	patients considered appropriate for radical therapy for localised disease may have
50	micro-metastases ⁷ .
51	
52	An alternative is positron emission tomography (PET), which can detect local and
53	distant prostate cancer cells ⁸ . ¹⁸ F-fluorodeoxyglucose is a tracer that is used in most
54	oncological PET scans ⁹ , as it has preferential uptake in cancer cells ¹⁰ . However,
55	early studies into its use in prostate cancer were not promising, with one study
56	showing a sensitivity of 37% $^{11-13}$, as such alternative PET tracers have been trialled
57	⁹ . These include Gallium-68 (⁶⁸ Ga) and Fluorine-18 (¹⁸ F) prostate-specific membrane
58	antigen (PSMA) PET.
59	

60 ⁶⁸Ga-PSMA-PET

⁶⁸Ga-PSMA-PET is a ligand that binds to PSMA – a glycoprotein that is
overexpressed on the surface of prostate cancer cells ⁸. In a randomised controlled
trial of 302 men with high-risk prostate cancer, Hofman et al. evaluated the accuracy
of ⁶⁸Ga-PSMA-PET versus CT and bone scan at detecting pelvic nodal or distant
metastatic disease. ⁶⁸Ga-PSMA-PET had significantly superior accuracy (92% v

66~65%, p<0.0001), as well as higher sensitivity (85% v 38%) and specificity (98% v

67 91%) compared to CT and bone scan¹⁴.

69	Petersen and Zacho conducted a systematic review of ⁶⁸ Ga-PSMA-PET for lymph
70	node staging in prostate cancer. In 18 studies including 969 patients, the weighted
71	sensitivity and weighted specificity compared to pathology as a reference was 59%
72	(range 23-100%) and 93% (range 67-100%), respectively. In four studies, 68 Ga-
73	PSMA-PET was superior to CT or MRI, but in three studies comparing ⁶⁸ Ga-PSMA-
74	PET to mpMRI (multiparametric MRI) or diffusion weighted MRI there were mixed
75	results ¹⁵ .
76	
77	⁶⁸ Ga-PSMA-PET may also be used to improve the detection of metastatic disease in
78	those with biochemical recurrence (BCR). In a systematic review of 37 studies
79	comprising 4790 patients, Perera et al. demonstrated that in patients with
80	biochemical recurrence (BCR) ⁶⁸ Ga-PSMA-PET positivity increased with increasing
81	PSA level, and could be used to detect recurrence at low PSA levels (⁶⁸ Ga-PSMA-
82	PET positivity for <0.2ng/ml was 33% and for 0,2-0.5ng/ml was 45%) 16 .
83	
84	Hofman et al. also found that first-line ⁶⁸ Ga-PSMA-PET changed management
85	intent, modality, or modality delivery more commonly compared to CT and bone scan
86	(28% v 15%, p=0.008). ⁶⁸ Ga-PSMA-PET was also associated with management
87	change in those who received in second-line compared to CT and bonne scan (27%
88	v 5%) ¹⁴ . Han et al. performed a systematic review of the impact of 68 Ga-PSMA-PET
89	on management decisions. 1163 patients across 15 studies were included, and there
90	were management changes in 54% (95% CI 47-60%) of patients following ⁶⁸ G-

PSMA-PET ¹⁷. ⁶⁸Ga-PSMA-PET positivity was significantly associated with increased
rate of management change and meta-regression demonstrated that for each
percent increase in positivity there was a 0.55% change in management (p<0.05).

95 ¹⁸**F-PSMA-PET**

A more recent development in PSMA-PET imaging is the use of ¹⁸F-PSMA-PET as an alternative tracer to ⁶⁸Ga, utilising the ¹⁸F radio-isotope ligand to label PSMA. One advantage of ¹⁸F is its minimal urinary excretion compared to ⁶⁸G, which is limited by primary excretion through the urinary system, resulting in accumulation in the bladder, obscuring the prostate ¹⁸. Furthermore, ¹⁸F has practical advantages over ⁶⁸Ga, including a longer half-life, aiding production of the agent in a central facility and distribution to distant imaging centres (Table 1) ¹⁸.

103

Prive et al compared ¹⁸F-PSMA-PET to conventional mp-MRI for local primary 104 staging, in a cohort of 55 patients with intermediate to high risk prostate cancer¹⁹. 23 105 106 patients received both imaging modalities and underwent radical prostatectomy, with 107 prostate specimens subsequently available for histopathological analysis. Using 108 histopathological T stage as reference, this study demonstrated ¹⁸F-PSMA-PET 109 correctly staged seminal vesical invasion (pT3b) more often than mp-MRI (90 vs 110 76%), whereas mp-MRI correctly staged extra-capsular extension (pT3a) more often than ¹⁸F-PSMA-PET (90 vs 57%). 111

112

Rowe et al evaluated ¹⁸F-PSMA-PET performance in distant lesion detection in
metastatic prostate cancer²⁰. Eight patients with biochemical recurrence underwent
both ¹⁸F-PSMA-PET and CT-bone scan. 139 sites of PET positive for metastatic

- 116 disease were detected, whereas only 45 sites of metastatic disease were identified
- 117 on CT-bone scan. Although metastatic deposit biopsy data was not available for
- 118 reference, regression analysis estimated 72% (95% CI 55-84%) of negative or
- 119 equivocal lesions on CT-bone scan would be positive on ¹⁸F-PSMA-PET.
- 120 Conversely, it was estimated that only 3% (95% CI 1-7%) of negative or equivocal
- 121 lesions on ¹⁸F-PSMA-PET would be positive on CT-bone scan.
- 122
- 123 Dietlein et al compared ¹⁸F-PSMA-PET to ⁶⁸Ga-PSMA-PET in the context of
- biochemically recurrent prostate cancer²¹. They performed PSMA-PET scans with
- 125 both tracers on 25 patients with biochemically recurrent prostate cancer. This
- 126 demonstrated non-inferiority of ¹⁸F-PSMA-PET and suggested its improved
- 127 sensitivity in localising relapsed tumours after prostatectomy in moderately raised
- 128 PSA contexts.
- 129

PET	Mechanism of targeting		Sites of		
Modality	Tracer	Target	physiological uptake	Advantages	Disadvantages
G68-PSMA- PET	Gallium- 68 radio- isotope	PSMA: transmembrane protein over- expressed in PCa	Kidney, bladder, salivary/lacrimal glands, liver, spleen, intestines	High prostatic specificity	Higher urinary clearance
F18-PSMA- PET	Fluorine- 18 radio- isotope	PSMA: transmembrane protein over- expressed in PCa	Kidney, salivary/lacrimal glands, liver, spleen, intestines	High prostatic specificity; Minimal urinary clearance	

- 130
- 131 Table 1: Comparison of different PET modalities for prostate cancer imaging
- 132
- 133 Our centre has performed ¹⁸F-PSMA PET since 2019 and we have conducted all
- 134 primary staging with this modality since August 2020. In this study, we aim to
- 135 examine the added value of ¹⁸F-PSMA PET over conventional staging modalities for

- 136 primary and secondary disease, local and distant disease, and to investigate the
- 137 influence of ¹⁸F-PSMA PET on treatment decisions.

138 Hypothesis

- ¹⁸F-PSMA PET has suitable accuracy for investigation of primary and secondary
- 140 prostate metastasis (nodal and distant) and alters management subsequently.

141 **Aims**

- Comparison of PSMA-PET vs mpMRI for T and N stage
- Comparison of PSMA-PET vs MRI marrow, MRI Narrow Slice, or bone scan
- 144 for M stage
- Comparison between imaging modalities for positive, negative, and equivocal
 results
- Comparison between imaging modalities and histology results
- Added value of PSMA-PET in clinically significant disease where there is a
- 149 discordance between pathology findings and biochemistry
- Impact of PSMA-PET for primary staging on decision making and treatment
 strategy
- Impact of PSMA-PET for secondary staging (BCR post radical local therapy)
- 153 on decision making and treatment strategy
- Influence of risk factors on the above aims e.g. PSA level or D'Amico risk
 classification.

156 **METHODOLOGY**

- 157 We will conduct a retrospective review of electronic patient records for all
- 158 consecutive patients who underwent preoperative ¹⁸F-PSMA PET scan for prostate
- 159 cancer from its introduction at the Churchill Hospital, Oxford, UK in 2019. Patients
- 160 will be identified from the list of PET scans held by the radiology department and
- 161 relevant data points will be collected (Table 2).
- 162 The STROBE (Strengthening the Reporting of Observational Studies in
- 163 Epidemiology) guidelines for cohort studies will be followed ²².

164 **PICOS**

- 165 Patients all patients with prostate cancer who underwent a PSMA PET scan
- 166 Intervention PET scan
- 167 Comparison mpMRI, MRI Marrow, Bone scan, Pathological stage
- 168 Outcome Diagnostic accuracy for stage & management implication
- 169 Study type retrospective consecutive cohort study

Demographics

Date of birth PSA at time of diagnosis D'Amico risk classification Primary or secondary prostate cancer Previous treatment for prostate cancer

Imaging

PSMA PET report PSMA PET date PSMA PET stage - T, N, M PSA at time of PSMA PET MRI report MRI date MRI stage - T, N MRI Highest PIRADS MRI prostate volume MRI Marrow – M stage Bone Scan – M stage Narrow slice MRI – positive or negative outcome

Biopsy / Histology

Biopsy / Histology report Biopsy / Histology date Grade Stage Positive margins Lymph node pathology

Decision making

Management decision MDT report / Clinic letter detailing decision Did PSMA PET impact decision making? Y/N

171

- 172 Table 2: Data points which we intend to collect. As this study is a retrospective study,
- 173 we may need to amend data points depending on whether the data is available

175 **REFERENCES**

- 176 1. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-
- 177 SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening,
- 178 Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2021;79(2):243-
- 179 262. doi:10.1016/j.eururo.2020.09.042
- 180 2. Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT
- and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:
- 182 a meta-analysis. *Clin Radiol*. 2008;63(4):387-395.
- 183 doi:10.1016/j.crad.2007.05.022
- 184 3. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive Detection of
- 185 Clinically Occult Lymph-Node Metastases in Prostate Cancer. *N Engl J Med.*

186 2003;348(25):2491-2499. doi:10.1056/nejmoa022749

- 187 4. Thoeny HC, Froehlich JM, Triantafyllou M, et al. Metastases in normal-sized
- 188 pelvic lymph nodes: Detection with diffusion-weighted MR imaging. *Radiology*.
- 189 2014;273(1):125-135. doi:10.1148/radiol.14132921
- 190 5. Kiss B, Thoeny HC, Studer UE. Current Status of Lymph Node Imaging in
- 191 Bladder and Prostate Cancer. *Urology*. 2016;96:1-7.
- 192 doi:10.1016/j.urology.2016.02.014
- 193 6. Mottet N, van den Bergh RCN, Briers E, et al. EAU-ESTRO-ESUR-SIOG
- 194 *Guidelines on Prostate Cancer.*; 2018. https://uroweb.org/wp-
- 195 content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-
- 196 large-text-V2.pdf. Accessed June 11, 2021.
- 197 7. Sathianathen NJ, Geurts N, Nair R, Lawrentschuk N, Murphy DG, Lamb AD.
- 198 The phytological future of prostate cancer staging: PSMA-PET and the
- dandelion theory. *Futur Oncol.* 2017;13(20):1801-1807. doi:10.2217/fon-2017-

201	8.	Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen
202		as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging.
203		2015;59(3):241-268. https://pubmed.ncbi.nlm.nih.gov/26213140/. Accessed
204		June 11, 2021.
205	9.	Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate
206		cancer PET tracers: Essentials for the urologist. Can J Urol. 2018;25(4):9371-
207		9383. https://pubmed.ncbi.nlm.nih.gov/30125515/. Accessed June 29, 2021.
208	10.	Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect:
209		The metabolic requirements of cell proliferation. Science (80-).
210		2009;324(5930):1029-1033. doi:10.1126/science.1160809
211	11.	Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with
212		FDG-PET scanning in prostate cancer show limited value for clinical practice.
213		Acta Oncol (Madr). 2002;41(5):425-429. doi:10.1080/028418602320405005
214	12.	Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-
215		18-fluorodeoxyglucose positron emission tomography is useless for the
216		detection of local recurrence after radical prostatectomy. Eur Urol.
217		1999;36(1):31-35. doi:10.1159/000019923
218	13.	Minamimoto R, Senda M, Jinnouchi S, et al. The current status of an FDG-
219		PET cancer screening program in Japan, based on a 4-year (2006-2009)
220		nationwide survey. Ann Nucl Med. 2013;27(1):46-57. doi:10.1007/s12149-012-
221		0660-x
222	14.	Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane
223		antigen PET-CT in patients with high-risk prostate cancer before curative-
224		intent surgery or radiotherapy (proPSMA): a prospective, randomised,

225 multicentre study. *Lancet*. 2020;395(10231):1208-1216. doi:10.1016/S0140-

226 6736(20)30314-7

- 227 15. Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of
- intermediate and high-risk prostate cancer: An expedited systematic review.
- 229 Cancer Imaging. 2020;20(1). doi:10.1186/s40644-020-0290-9
- 230 16. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane
- 231 Antigen Positron Emission Tomography in Advanced Prostate Cancer—
- 232 Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-
- 233 specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-
- 234 analysis. *Eur Urol*. 2020;77(4):403-417. doi:10.1016/j.eururo.2019.01.049
- 235 17. Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the
- 236 Management of Patients with Prostate Cancer: A Systematic Review and
- 237 Meta-analysis. *Eur Urol.* 2018;74(2):179-190.
- 238 doi:10.1016/j.eururo.2018.03.030
- 239 18. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007:
- 240 biodistribution, radiation dosimetry and histopathological validation of tumor
- 241 lesions in prostate cancer patients. *Eur J Nucl Med Mol Imaging*.
- 242 2017;44(4):678-688. doi:10.1007/s00259-016-3573-4
- 243 19. Privé BM, Israël B, Schilham MGM, et al. Evaluating F-18-PSMA-1007-PET in
- 244 primary prostate cancer and comparing it to multi-parametric MRI and
- histopathology. *Prostate Cancer Prostatic Dis.* 2021;24(2):423-430.
- 246 doi:10.1038/s41391-020-00292-2
- 247 20. Rowe SP, Macura KJ, Mena E, et al. PSMA-Based [(18)F]DCFPyL PET/CT Is
- 248 Superior to Conventional Imaging for Lesion Detection in Patients with
- 249 Metastatic Prostate Cancer. *Mol imaging Biol.* 2016;18(3):411-419.

250 doi:10.1007/s11307-016-0957-6

- 251 21. Dietlein F, Kobe C, Neubauer S, et al. PSA-Stratified Performance of (18)F-
- and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate
- 253 Cancer. J Nucl Med. 2017;58(6):947-952. doi:10.2967/jnumed.116.185538
- 254 22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
- 255 JP. The Strengthening the Reporting of Observational Studies in Epidemiology
- 256 (STROBE) statement: guidelines for reporting observational studies. *Lancet*.
- 257 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X